TY - JOUR T1 - Treatment of Early Hypertension among Persons Living with HIV in Haiti: protocol for a randomized controlled trial JF - medRxiv DO - 10.1101/2021.04.13.21255408 SP - 2021.04.13.21255408 AU - Lily D Yan AU - Vanessa Rouzier AU - Eliezer Dade AU - Collette Guiteau AU - Jean Lookens Pierre AU - Stephano St-Preux AU - Miranda Metz AU - Suzanne Oparil AU - Jean William Pape AU - Margaret McNairy Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/04/16/2021.04.13.21255408.abstract N2 - Background People living with HIV (PLWH) are at increased risk of cardiovascular disease (CVD) and death, with greater burdens of both HIV and CVD in lower-middle income countries. Treating prehypertension in PLWH may reduce progression to hypertension, CVD risk and potentially mortality. However, no trial has evaluated earlier blood pressure treatment for PLWH. We propose a randomized controlled trial to assess the feasibility, benefits, and risks of initiating antihypertensive treatment among PLWH with prehypertension, comparing prehypertension treatment to standard of care following current WHO guidelines.Methods A total of 250 adults 18-65 years and living with HIV (PLWH) with viral suppression in the past 12 months, who have prehypertension will be randomized to prehypertension treatment versus standard of care. Prehypertension is defined as having a systolic blood pressure (SBP) 120-139 mmHg or diastolic blood pressure (DBP) 80-89 mmHg. In the prehypertension treatment arm, participants will initiate amlodipine 5 mg daily immediately. In the standard of care arm, participants will initiate amlodipine only if they develop hypertension defined as SBP ≥ 140 mmHg or DBP ≥ 90 mmHg. The primary outcome is the difference in mean change of SBP from enrollment to 12 months. Secondary outcomes include feasibility, acceptability, adverse effects, HIV viral suppression, and medication adherence. Qualitative in-depth interviews with providers and participants will explore attitudes about initiating amlodipine, satisfaction, perceived CVD risk, and implementation challenges.Discussion PLWH have a higher CVD risk and may benefit from a lower BP threshold for initiation of antihypertensive treatment.Trial registration Clinicaltrials.gov registration number NCT04692467, registration date December 15, 2020, protocol ID 20-03021735.Competing Interest StatementVR, JWP, MLM report a grant from the Fogarty International Center, grant number R21 TW011693. The remaining authors declare they have no conflicts of interest.Clinical TrialNCT04692467Funding StatementFunding for this study comes from the Fogarty International Center, grant number R21 TW011693. The funders had no role in the study design or execution of this protocol.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by institutional review boards at Weill Cornell Medicine and GHESKIO.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets to be collected during the current study will be available from the corresponding author on reasonable request. Data request should be submitted to Dr. Margaret McNairy (mam9365@med.cornell.edu) who will review the data request with Haiti GHESKIO Site PI, Dr. Jean Pape and the study's Data Safety Monitoring Board for approval. ER -